| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 813 | 2018 |
| Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients F Mouliere, R Mair, D Chandrananda, F Marass, CG Smith, J Su, J Morris, ... EMBO molecular medicine 10 (12), e9323, 2018 | 144 | 2018 |
| High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA D Chandrananda, NP Thorne, M Bahlo BMC medical genomics 8, 1-19, 2015 | 142 | 2015 |
| ctDNA monitoring using patient-specific sequencing and integration of variant reads JCM Wan, K Heider, D Gale, S Murphy, E Fisher, F Mouliere, ... Science translational medicine 12 (548), eaaz8084, 2020 | 138 | 2020 |
| Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients B Risberg, DWY Tsui, H Biggs, ARVM de Almagro, SJ Dawson, ... The Journal of Molecular Diagnostics 20 (6), 883-892, 2018 | 92 | 2018 |
| Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer KM Patel, KE Van Der Vos, CG Smith, F Mouliere, D Tsui, J Morris, ... Scientific reports 7 (1), 5554, 2017 | 92 | 2017 |
| Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors CG Smith, T Moser, F Mouliere, J Field-Rayner, M Eldridge, AL Riediger, ... Genome medicine 12, 1-17, 2020 | 85 | 2020 |
| Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models R Mair, F Mouliere, CG Smith, D Chandrananda, D Gale, F Marass, ... Cancer research 79 (1), 220-230, 2019 | 84 | 2019 |
| Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients F Mouliere, CG Smith, K Heider, J Su, Y van der Pol, M Thompson, ... EMBO molecular medicine 13 (8), e12881, 2021 | 73 | 2021 |
| Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer DWY Tsui, M Murtaza, ASC Wong, OM Rueda, CG Smith, ... EMBO molecular medicine 10 (6), e7945, 2018 | 68 | 2018 |
| Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA I Hudecova, CG Smith, R Hänsel-Hertsch, CS Chilamakuri, JA Morris, ... Genome research 32 (2), 215-227, 2022 | 42 | 2022 |
| Investigating and correcting plasma DNA sequencing coverage bias to enhance aneuploidy discovery D Chandrananda, NP Thorne, D Ganesamoorthy, DL Bruno, Y Benjamini, ... PLoS One 9 (1), e86993, 2014 | 30 | 2014 |
| Refined characterization of circulating tumor DNA through biological feature integration H Markus, D Chandrananda, E Moore, F Mouliere, J Morris, JD Brenton, ... Scientific reports 12 (1), 1928, 2022 | 29 | 2022 |
| Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients–initial observations L Nygård, LB Ahlborn, GF Persson, D Chandrananda, JW Langer, ... PLoS One 15 (4), e0231884, 2020 | 14 | 2020 |
| The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection Y van der Pol, N Moldovan, J Ramaker, S Bootsma, KJ Lenos, ... Genome Biology 24 (1), 229, 2023 | 5 | 2023 |
| Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass S Hollizeck, SQ Wong, B Solomon, D Chandrananda, SJ Dawson Bioinformatics 37 (21), 3916-3919, 2021 | | 2021 |
